Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 17/20 | 0.80 |
| ▸ | PDE4B | Q07343 | 15/20 | 0.80 |
| ▸ | PDE4C | Q08493 | 15/20 | 0.80 |
| ▸ | PDE4D | Q08499 | 15/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5470083 | 0.92 | PDE4A (0.80) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL13031020 | 0.92 | PDE4A (0.80) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7444856 | 0.91 | PDE4A (0.81) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL13031021 | 0.91 | PDE4A (0.78) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5740782 | 0.90 | PDE4A (0.74) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5475820 | 0.90 | PDE4A (0.84) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5471486 | 0.88 | PDE4A (0.71) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3541858 | 0.87 | PDE4B (0.73) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3551823 | 0.86 | PDE4B (0.72) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3549971 | 0.86 | PDE4B (0.72) | PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070259874-A1 | Phosphodiesterase Inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2007-11-08 | — | — | US | disclosed |
| EP-1694655-A2 | PHOSPHODIESTERASE INHIBITORS | Ranbaxy Laboratories Limited (IN) | 2006-08-30 | — | — | EP | disclosed |
| WO-2005051931-A2 | PHOSPHODIESTERASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2005-06-09 | — | — | WO | disclosed |
| US-6114367-A | SUCH AS 3-(3-CYCLOPENTYLOXY-4-METHOXY)PHENYL-2-ISOXAZOLINE-5-HYDROXAMIC ACID; TREATING SEPSIS, SEPTIC SHOCK, INFLAMMATORY BOWEL DISEASE, TUBERCULOSIS, GRAFT VERSUS HOST DISEASE OR CACHEXIA ASSOCIATED WITH AIDS OR CANCER IN A MAMMAL | PFIZER INC (US) | 2000-09-05 | — | — | US | disclosed |
| US-5869511-A | Isoxazoline compounds as inhibitors of TNF release | PFIZER INC. (US) | 1999-02-09 | — | — | US | disclosed |
| EP-0749428-B1 | ISOXAZOLINE COMPOUNDS AS INHIBITORS OF TNF RELEASE | PFIZER (US) | 1998-07-29 | — | — | EP | disclosed |
| US-5716967-A | SELECTIVE INHIBITOR OF PHOSPHODIESTERASE TYPE 4, USEFUL IN TREATMENT OF ASTHMA, ARTHRITIS, BRONCHITIS, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, PSORIASIS, ALLERGIC RHINITIS, DERMATITIS OR SHOCK | PFIZER INC. (US) | 1998-02-10 | — | — | US | disclosed |
| EP-0730588-B1 | ISOXAZOLINE COMPOUNDS AS ANTIINFLAMMATORY AGENTS | PFIZER (US) | 1997-07-02 | — | — | EP | disclosed |
| EP-0730588-A1 | ISOXAZOLINE COMPOUNDS AS ANTIINFLAMMATORY AGENTS | PFIZER (US) | 1996-09-11 | — | — | EP | disclosed |
| WO-1995014681-A1 | ISOXAZOLINE COMPOUNDS AS ANTIINFLAMMATORY AGENTS | PFIZER INC. (US) | 1995-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259874-A1 | Phosphodiesterase Inhibitors | PDE4A, PDE3B, PDE7A | PDE4A 1/4885PDE4B 4/4885PDE4C 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.